Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)
Advertisement

Related Content

Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer
Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer
India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry
India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
PharmAsia News Notable Notes: GSK India Aims For Nine Product Launches In Two Years
India Patent Office to Make Key Decision on Export of Roche, Pfizer Cancer Drugs
Testing Times For India’s Drug Patent Law
Advertisement
UsernamePublicRestriction

Register

SC068091

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel